Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia Clinical Trial

Official title:

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04838041
• Other study ID #: PRO00040685
• Status: Recruiting
• Phase: Phase 2
• Start date: November 11, 2021
• Est. completion date: July 2029

Study information

• Verified date: April 2024
• Source: Medical College of Wisconsin
• Contact: Medical College of Wisconsin Cancer Center Clinical Trials Offic
• Phone: 414-805-8900
• Email: cccto[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.

Description:

All eligible patients will begin asciminib in combination with a TKI on cycle 1 day 1 of the combination phase. They will continue combination therapy for a total of 12 cycles (minimum of 12 months). Each cycle will be ~28 days. At the end of 12 cycles asciminib will be discontinued and any patient who has met the criteria for the treatment free remission (TFR) screening phase will enter into the TFR phase. Once in the TFR phase, patients will also discontinue their TKI and be monitored off treatment. The primary endpoint of this study is the 12-month 'second' TFR rate after completion of 12 cycles of combination therapy. Patients will remain in the TFR phase of the study for up to three years and will have central PCR testing during the first two years. Therefore, the total duration of the subject participation trial will be approximately five years (one year on combination treatment phase plus three years in the TFR phase plus one year of long-term follow-up post TFR or early discontinuation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 51
• Est. completion date: July 2029
• Est. primary completion date: June 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years old.

2. Willing and able to give informed consent.

3. Diagnosed with chronic myelogenous leukemia (CML) in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR::ABL1 protein. Subtype classification whether b3a2 (e14a2) or b2a2 (e13a2) is not required for study eligibility.

4. Must have a documented history of attempting only one prior TKI discontinuation under the guidance of a treating physician. TKI includes dasatinib, imatinib or nilotinib.

5. Must have met all the following criteria prior to first attempt to discontinue their TKI:

• Stable molecular response (MR4; < 0.01% IS) for > 2 years (with allowance for a two-week variance), as documented on at least four tests, performed at least three months apart (e.g., If a patient has had >4 PCR tests performed during the two years leading up to their initial TKI discontinuation, any value between 0.01 and 0.05% IS is considered a stable result, however, at least four tests must be < 0.01% IS. If any results are >0.05% IS, tests must have been repeated within one month and be less than 0.01% IS and stable.

• Treatment with one of the following FDA approved TKIs; imatinib, dasatinib, nilotinib at any dose for a minimum of approximately three years (allowance of a four-week variance) prior to discontinuing TKIs.

• Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed).

6. Must have relapsed (defined as loss of major molecular response (MMR), RQ-PCR for BCR::ABL1 >0.1% IS after first attempted TKI discontinuation.

7. After first failed TFR attempt, must have a minimum duration of one year of retreatment with TKI, and must plan to remain on that TKI for a minimum of 12 months during the combination treatment phase.

8. Current TKI must be the same as the TKI being taken prior to the initial TFR attempt (e.g., if patient is on imatinib prior to first TFR attempt, they should be on imatinib at time of enrollment on this study).

9. Eastern Cooperative Oncology Group (ECOG) performance status 0-3.

10. Must have a RQ-PCR for BCR::ABL1 < 0.0032% IS (MR4.5) reported by the trial designated central lab at the time of study enrollment.

11. Lipase = 1.5 x upper limit of normal (ULN). For lipase > ULN - = 1.5 x ULN, value should be considered not clinically significant and not associated with risk factors for acute pancreatitis.

12. Female patients must meet one of the following:

• Postmenopausal for at least one year before the screening visit,

• Surgically sterile

• If they are of childbearing potential, agree to practice two effective methods of contraception from the time of signing of the informed consent form through 90 days after the last dose of study drug,

• Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)

13. Male patients, even if surgically sterilized (i.e., status post vasectomy), must agree to one of the following:

• Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose.

• Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable.

• Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria:

1. History of accelerated or blast phase CML.

2. A second malignancy requiring active treatment.

3. History of recent (within 12 months) acute pancreatitis or chronic pancreatitis.

4. Subjects who have previously received treatment with asciminib.

5. Subjects with platelet (PLT) count < 100 × 109/L or an absolute neutrophil count (ANC) of < 1 × 109/L or hemoglobin < 8 g/dL.

6. Aspartate aminotransferase (AST) and alanine transaminase (ALT) =3 times the institutional upper limit of normal.

7. Creatinine clearance < 40 mL/min.

8. Total bilirubin = 1.5 times the institutional upper limit of normal (unless direct bilirubin is within normal limits).

9. Pregnant or lactating.

10. Unable to comply with lab appointment schedule and patient-reported outcome (PRO) assessments.

11. Another investigational drug within four weeks of enrollment.

12. Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol.

13. Patient has undergone a prior allogeneic stem cell transplant.

14. Screening 12-lead electrocardiogram (ECG) showing a baseline corrected QT interval >480msec (patients with a pacemaker will still be eligible with QTc>500msec).

15. Known active hepatitis B infection.

Eligibility for TFR Phase:

1. Stable molecular response (MR4.5; < 0.0032% IS) documented on at least three tests (may include TFR phase screening PCR) by the trial designated lab, performed approximately three months apart while on combination phase.

2. TFR phase screening PCR RQ-PCR for BCR::ABL1 < 0.0032% IS (MR4.5) by the trial designated lab.

3. ECOG 0-3.

4. Completion of 12 cycles on the combination therapy phase.

Related Conditions & MeSH terms

• Chronic Phase Chronic Myelogenous Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Chronic-Phase

Intervention

Drug:
• Asciminib 40 MG
40 mg by mouth (PO) when used with imatinib.
• Asciminib 40 MG Twice Daily
40 mg twice daily when used with nilotinib.
• Asciminib 80 MG daily
80 mg daily when used with dasatinib.
• Imatinib
Maximum dose of 400 mg PO once daily.
• Nilotinib
Maximum dose of 300 mg twice daily.
• Dasatinib
Maximum dose of 100 mg PO once daily.

Locations

Country	Name	City	State
United States	The Barbara Ann Karmanos Cancer Institute	Detroit	Michigan
United States	Froedtert Hospital & the Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
Medical College of Wisconsin	H. Jean Khoury Cure CML Consortium

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	One-year "second" treatment-free remission.	This will be measured by the number of subjects who achieve one-year treatment-free remission after 12 months of combination therapy with TKI plus asciminib. These subjects have previously failed a first treatment free remission attempt.	1 year